- Epithelial Ovarian Tumor
- Ovarian Germ Cell Tumor
- Ovarian Stomatal Tumor
- Primary Peritoneal Carcinoma
Ovarian Cancer Treatment Market size was valued at 2.2 billion in 2022 and is expected to reach 3.6 billion by 2029, at a CAGR of 7.1% during the forecast period 2023 to 2029. Ovarian cancer is a type of cancer, which affects ovaries it causes rapid and abnormal increase of cell growth in ovaries. The exact cause of cancer is still unknown. An epithelial tumour, germ cell tumour and primary peritoneal carcinoma are types of ovarian cancer. Common symptoms include pressure in pelvis or lower back, changes in bowel movements, tiredness or low energy and more frequent urination. In most of the ovarian cancer cases, cancer will not be diagnosed until it has progressed to an advanced stage. Ovarian cancer is one of most common cause of cancer deaths in women. Thereby need for development of the more effective drugs in treatment of ovarian cancer. Companies operating in ovarian cancer market investing in developing new drug therapies and finding newer molecular targets to treat ovarian cancer. For instance, Vintafolide an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. and faltetuzumab a monoclonal antibody being investigated for the treatment of ovarian cancer this was developed by Morphotek, Inc. The introduction of new drug therapies like gene therapy, radiation therapy and targeted drug therapy are projected to improve ovarian cancer market revenue growth over forecast period. Global ovarian cancer market currently dominated by generic drugs and development of more effective drugs is challenging for market players. Some of the new drugs like avastin, lynparza and yondelis are approved in recent years to treat cancer and these drugs are slowly capturing market share.
Ovarian Cancer Treatment Market Key Developments:
- In December 2018 FDA approved rucaparib for the treatment of woman with advanced ovarian cancer who have received two or more prior chemotherapies and whose tumours have BRCA gene mutation
Global Ovarian Cancer Treatment Market Summary
Study Period
2023-29
Base Year
2022
CAGR
7.1%
Largest Market
Europe
Fastest Growing Market
North-America
Ovarian Cancer Treatment Market Dynamics
Increase in incidence of ovarian cancer worldwide is driving the ovarian cancer treatment market. According to WHO, an estimated 238,700 woman are diagnosed with ovarian cancer in 2012. The increase in older woman population, rising government funding and raising health care awareness able to grow ovarian cancer treatment market over the forecast period. According to ovarian cancer research fund alliance, the rate of prevalence of ovarian cancer is higher in woman between 55 to 66 years, many of the cancer foundations are funding to educate patients and healthcare professionals regarding symptoms and treatment options for ovarian cancer which may impact ovarian cancer market revenue growth positively over a forecast period. However, availability of generic drugs, lack of accurate diagnosis of ovarian cancer, and patient expiry of the key patented drugs like gemzar, taxol and paraplatin are expected to hamper the ovarian cancer treatment market.
North-America Got Significant Share
Ovarian Cancer Treatment Market Regional Analysis
Geographically ovarian cancer treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the ovarian cancer treatment market due to rising number of ageing population. According to American cancer society, in U.S. about 22,440 women will receive a new diagnosis of ovarian cancer and about 14,080 women will die from ovarian cancer in 2017. Europe is largest market as the incidence rates of ovarian cancer is increased in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Ovarian Cancer Treatment Market Segmentation
By Type of Cancer
Drug Class
- Chemotherapeutic Agents
- Targeted Therapy Drugs
- Immune System Modulators
- Hormones
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Frequently Asked Questions
The ovarian cancer treatment market size was valued at USD 2.2 billion in 2022
The ovarian cancer treatment market key players are: Johnson & Johnson Services Inc. (U.S.) Eli Lilly and Company (U.S.) Novogen Limited (Australia) Aeterna Zentaris Inc. (U.S) GlaxoSmithKline plc (UK) Boehringer Ingelheim GmbH (Germany) F. Hoffmann-La Roche AG (Switzerland)
The ovarian cancer treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Ovarian Cancer Treatment Market Introduction |
| 2.1. Global Ovarian Cancer Treatment Market – Taxonomy |
| 2.2. Global Ovarian Cancer Treatment Market –Definitions |
| 2.2.1. Drug Class |
| 2.2.2. Cancer Type |
| 2.2.3. Distribution Channel |
| 2.2.4. Region |
| 3. Global Ovarian Cancer Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Ovarian Cancer Treatment Market Dynamic Factors - Impact Analysis |
| 3.6. Ovarian Cancer Epidemiology |
| 3.7. Pipeline Analysis |
| 3.8. Target or Mechanism of Action Analysis |
| 3.9. Patient Journey |
| 3.10. Collaborations, Distribution Agreements, and Acquisitions |
| 4. Global Ovarian Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Ovarian Cancer Treatment Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Chemotherapeutic Agents |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Targeted Therapy Drugs |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Immune System Modulators |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Hormones |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Ovarian Cancer Treatment Market Forecast, By Cancer Type, 2018 - 2022 and Forecast, 2023 - 2029 |
| 6.1. Epithelial Ovarian Tumor |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Ovarian Germ Cell Tumor |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Ovarian Stomatal Tumor |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Primary Peritoneal Carcinoma |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Global Ovarian Cancer Treatment Market, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Others |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Ovarian Cancer Treatment Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Region, 2023 - 2029 |
| 9. North America Ovarian Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Chemotherapeutic Agents |
| 9.1.2. Targeted Therapy Drugs |
| 9.1.3. Immune System Modulators |
| 9.1.4. Hormones |
| 9.2. Cancer Type Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Epithelial Ovarian Tumor |
| 9.2.2. Ovarian Germ Cell Tumor |
| 9.2.3. Ovarian Stomatal Tumor |
| 9.2.4. Primary Peritoneal Carcinoma |
| 9.2.5. Others |
| 9.3. Distribution Channel Type Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. Hospital Pharmacies |
| 9.3.2. Retail Pharmacies |
| 9.3.3. Others |
| 9.4. Country Analysis 2017 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. U.S. |
| 9.4.2. Canada |
| 9.5. North America Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, and Country, 2023 - 2029 |
| 9.6. North America Ovarian Cancer Treatment Market Dynamics – Trends |
| 10. Europe Ovarian Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Chemotherapeutic Agents |
| 10.1.2. Targeted Therapy Drugs |
| 10.1.3. Immune System Modulators |
| 10.1.4. Hormones |
| 10.2. Cancer Type Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Epithelial Ovarian Tumor |
| 10.2.2. Ovarian Germ Cell Tumor |
| 10.2.3. Ovarian Stomatal Tumor |
| 10.2.4. Primary Peritoneal Carcinoma |
| 10.2.5. Others |
| 10.3. Distribution Channel Type Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Hospital Pharmacies |
| 10.3.2. Retail Pharmacies |
| 10.3.3. Others |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. Spain |
| 10.4.4. France |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Rest of Europe |
| 10.5. Europe Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel and Country, 2023 - 2029 |
| 10.6. Europe Ovarian Cancer Treatment Market Dynamics – Trends |
| 11. Asia-Pacific Ovarian Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Chemotherapeutic Agents |
| 11.1.2. Targeted Therapy Drugs |
| 11.1.3. Immune System Modulators |
| 11.1.4. Hormones |
| 11.2. Cancer Type Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Epithelial Ovarian Tumor |
| 11.2.2. Ovarian Germ Cell Tumor |
| 11.2.3. Ovarian Stomatal Tumor |
| 11.2.4. Primary Peritoneal Carcinoma |
| 11.2.5. Others |
| 11.3. Distribution Channel Type Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Hospital Pharmacies |
| 11.3.2. Retail Pharmacies |
| 11.3.3. Others |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2023 - 2029 |
| 11.6. Asia-Pacific Ovarian Cancer Treatment Market Dynamics – Trends |
| 12. Latin America Ovarian Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 12.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Chemotherapeutic Agents |
| 12.1.2. Targeted Therapy Drugs |
| 12.1.3. Immune System Modulators |
| 12.1.4. Hormones |
| 12.2. Cancer Type Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Epithelial Ovarian Tumor |
| 12.2.2. Ovarian Germ Cell Tumor |
| 12.2.3. Ovarian Stomatal Tumor |
| 12.2.4. Primary Peritoneal Carcinoma |
| 12.2.5. Others |
| 12.3. Distribution Channel Type Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Hospital Pharmacies |
| 12.3.2. Retail Pharmacies |
| 12.3.3. Others |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Rest of Latin America |
| 12.5. Latin America Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2023 - 2029 |
| 12.6. Latin America Ovarian Cancer Treatment Market Dynamics – Trends |
| 13. Middle East and Africa Ovarian Cancer Treatment Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 13.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Chemotherapeutic Agents |
| 13.1.2. Targeted Therapy Drugs |
| 13.1.3. Immune System Modulators |
| 13.1.4. Hormones |
| 13.2. Cancer Type Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Epithelial Ovarian Tumor |
| 13.2.2. Ovarian Germ Cell Tumor |
| 13.2.3. Ovarian Stomatal Tumor |
| 13.2.4. Primary Peritoneal Carcinoma |
| 13.2.5. Others |
| 13.3. Distribution Channel Type Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1. Hospital Pharmacies |
| 13.3.2. Retail Pharmacies |
| 13.3.3. Others |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Saudi Arabia |
| 13.4.2. South Africa |
| 13.4.3. Rest of MEA |
| 13.5. MEA Ovarian Cancer Treatment Market - Opportunity Analysis Index, By Drug Class, Cancer Type, Distribution Channel, and Country, 2023 - 2029 |
| 13.6. MEA Ovarian Cancer Treatment Market Dynamics – Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Eli Lilly and Company |
| 14.2.2. Johnson & Johnson Services, Inc. |
| 14.2.3. Kazia Therapeutics |
| 14.2.4. Aeterna Zentaris Inc |
| 14.2.5. GlaxoSmithKline plc |
| 14.2.6. F. Hoffmann-La Roche AG |
| 14.2.7. AbbVie Inc., |
| 14.2.8. Pfizer Inc., |
| 14.2.9. AstraZeneca plc |
| 14.2.10. Immunogen |
| 14.2.11. Novartis |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
- Johnson & Johnson Services Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Novogen Limited (Australia)
- Aeterna Zentaris Inc. (U.S)
- GlaxoSmithKline plc (UK)
- Boehringer Ingelheim GmbH (Germany)
- F. Hoffmann-La Roche AG (Switzerland)